Skip to main content
. Author manuscript; available in PMC: 2020 Dec 4.
Published in final edited form as: Circ Cardiovasc Qual Outcomes. 2019 Nov 12;12(11):e000057. doi: 10.1161/HCQ.0000000000000057
Committee Member Employment Consultant Speakers Bureau Ownership/Partnership/Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness
Donald E. Casey Jr, Chair Thomas Jefferson College of Population Health—Adjunct Faculty; Rush Medical College—Faculty; University of Minnesota, Institute of Health Informatics—Affiliate Faculty; President, American College of Medical Quality; IPO 4 Health—Principal and Founder None None None None None None
Randal J. Thomas, Vice Chair Mayo Clinic—Medical Director, Cardiac Rehabilitation Program None None None None None None
Vivek Bhalla Stanford University Medical Center—Assistant Professor of Medicine, Nephrology; Stanford Hypertension Center—Director
  • Relypsa, Inc.

None None None
  • PyrAmes Health

None
Yvonne Commodore-Mensah Johns Hopkins School of Nursing—Assistant Professor None None None None None None
Paul A. Heidenreich Stanford VA Palo Alto Health Care System—Professor of Medicine None None None None None None
Dhaval Kolte Massachusetts General Hospital and Harvard Medical School—International Cardiology Fellow None None None None None None
Paul Muntner University of Alabama at Birmingham—Professor, Department of Epidemiology None None None None None None
Sidney C. Smith Jr University of North Carolina at Chapel Hill—Professor of Medicine; Division of Cardiology, Department of Medicine None None None None None None
John A. Spertus Washington University School of Medicine in St. Louis—Adjunct Professor of Medicine, Cardiovascular Division; Saint Luke’s Mid America Heart Institute—Director, Health Outcomes Research; University of Missouri-Kansas City—Professor, Daniel J. Lauer Missouri Endowed Chair in Metabolism and Vascular Disease Research
  • AstraZeneca*

  • Bayer Healthcare Pharmaceuticals

  • Boehringer Ingelheim*

  • Janssen*

  • Novartis*

None None None
  • AstraZeneca UK Limited

  • Novartis*

None
John R. Windle University of Nebraska College of Medicine—Professor, Internal Medicine, Division of Cardiovascular Medicine None None None None None None
Gregory D. Wozniak American Medical Association—Director, Outcomes Analytics; Northwestern University, Feinberg School of Medicine—Adjunct Assistant Professor None None None None None None
Boback Ziaeian UCLA David Geffen School of Medicine—Assistant Professor; US Department of Veterans Affairs—Assistant Professor None None None None None None

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

*

Significant relationship.

No financial benefit.

ACC indicates American College of Cardiology; AHA, American Heart Association; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.